SCANDION ONC
Share · DK0061031895 · A2N9BV (XSTO)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SCANDION ONC
No Price
Company Profile for SCANDION ONC Share
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
Company Data
Name SCANDION ONC
Company Scandion Oncology A/S
Website
https://www.scandiononcology.com
Primary Exchange 
NASDAQ STOCKHOLM AB
NASDAQ STOCKHOLM AB
WKN A2N9BV
ISIN DK0061031895
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Francois Regis Martelet
Country Denmark
Currency EUR
Employees 0,0 T
Address Symbion, 2100 Copenhagen
IPO Date 2018-11-08
Stock Splits
| Date | Split |
|---|---|
| 31.05.2024 | 447:250 |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ STOCKHOLM AB | SCOL.ST |
| Frankfurt | 8VY.F |
More Shares
Investors who hold SCANDION ONC also have the following shares in their portfolio:
